Introduction

    • Volume/IssueClick here
    • Review ProcessDouble Blind
      • Publication lead time3 - 4 weeks
      • Indexing statusYes; Purview
      • Manuscript Processing ChargesClick here
      • Submission ChargesNo
      • Waiver policy for APCYes
      • Language of Full TextEnglish
      • Full-text formats availablePDF, HTML
    • Show +
    • Permanent article identifierDOI (Digital Object Identifier) We provide DOI to all published papers to facilitate higher citation and classification of articles.
      Peertechz Publisher ID: 10.17352
    • Type of LicenseCreative Commons
      • Open AccessYes; Policy
      • Does the author retain unrestricted copyright?Yes
      • Does the author retain publishing rights?Yes
    • Show +

    Editor-in-Chief

    M.Waheed Roomi

    M.Waheed Roomi
    Dr. Rath Research Institute
    1260 Memorex Drive, Santa Clara, USA
    Email: w.roomi@drrath.com
    Tel: (408)730-4481
    Fax: (408) 588-7174

    More Info.

    Tsuyoshi Shirakawa

    Tsuyoshi Shirakawa
    Kyushu University, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
    Email: t-w-r@intmed1.med.kyushu-u.ac.jp
    Tel: +81-92-661-5395
    Fax: +81-955-70-1511

    More Info.


    Welcome from the desk of

    Dr. Tsuyoshi Shirakawa, MD., Executive Editor

    Welcome to our website! I am very happy for your visit.

    Global Journal of Cancer Therapy reports both clinical and experimental results related to cancer, and is using online review and Editorial Manager System for quality review process. The Journal invites all type of clinical and medical case reports, case studies, basic researches, clinical images, pharmacology and nursing, as it were, total oncology. The goal of us is to keep a record of the state-of-the-art research or case report and to promote study, research and improvement within its various specialties, then to develop total oncology.

    We believe your expertise knowledge will help in the growth of the journal and as well help many budding research scientists all around the world. Your article will be a key insight into real medical cases that are essential for physicians, and may ultimately help to improve patient outcomes.

    Editorial Board

    Fan Song
    Sun Yat-Sen University
    China
    fansong8888@163.com
    GJCT

    Research Interest: Minimal Invasion, Endoscopically Assisted Selective Neck Dissection, Functional Reconstruction, Mitochondrial Fission, Cisplatin Sensitivity, Mirna, Lncrna


    More Info.
    Grivas Nikolaos
    Associate Member of EAU
    University of Ioannina
    Greece
    ngrivas@cc.uoi.gr
    GJCT

    Research Interest: Bladder Cancer, Prostate Cancer, Renal Cancer, Urolithiasis And Uro-Gynaecology.

    More Info.
    Wei Du
    Hematology and Cancer Biology
    Cincinnati Childrens Hospital Medical Center
    USA
    Wei.Du@cchmc.org
    GJCT

    Research Interest: Stem Cell Biology And Pathophysiology Of Bone Marrow Failure And Leukemia; Identifying And Targeting The Alternative Oxidative DNA-Damage Response Pathways Required For Cancer Progression; The Role Of A Major Proliferating Protein, Nucleophosmin (NPM) In Cancer Development


    More Info.
    Leonard Amaral
    Professor
    Universidade Nova de Lisboa
    Portugal
    LAmaral@ihmt.unl.pt
    GJCT

    Research Interest: Bacteriology, Immunology, Hematology, Clinical Pathology, Chemical Pathology, Endocrinology, Cancer, Human Embryology, Methods For Clinical Laboratories


    More Info.
    Kailash Chadha
    Department of Molecular and Cellular Biology
    Roswell Park Cancer Institute
    USA
    Kailash.Chadha@RoswellPark.org
    GJCT

    Research Interest: The Physiological Role Of PSA In Prostate Tissue Microenvironment, In Prostate Tumor Growth And Progression, And In Prostate Cancer Metastasis Is Not Known. Attenuation Of PSA Levels With Age, Disease Progression, Or During Androgen Deprivation Therapy, However, Removes This Important Regulator Of Angiogenesis, And By Extension Results In Tumor Progression. Re-Introduction Of Human PSA Into The Prostate Tissue Microenvironment May Suppress Tumor Angiogenesis Through Either The Inhibition Of Expression Of Pro-Angiogenic Genes Or Induction Of Expression Of Anti-Angiogenic Genes, Or Via Inhibition Of Signaling Mechanisms Associated With Angiogenesis That Are Independent Of Gene Transcription. Validation Of An Anti-Angiogenic Effect Of PSA On The Human Tissue Vasculature In A Pre-Clinical Model Of Primary Xenografts Of Human Prostate And Prostate Cancer Tissue Will Provide Compelling Evidence That PSA Has Therapeutic Potential Against Prostate Cancer.



    More Info.
    Gang Du
    Shanghai Jiaotong University
    China
    gdu@dbm.ecnu.edu.cn
    GJCT
    Research Interest: Clinical Tumour Classification And Diagnosis, Data Mining In Healthcare, Clinical Pathway Modeling, Simulation And Scheduling Optimization, Decision-Making In Healthcare  
    More Info.
    Mirela Sedic
    Assistant Professor
    Department of Biotechnology
    University of Rijeka
    Croatia
    msedic@biotech.uniri.hr
    GJCT

    Research Interest: Her Major Scientific Interests Include Cancer Biology And Treatment, With Particular Emphasis On Sphingolipid Signalling In Cancer.


    More Info.
    Rui-An Wang
    Professor
    Department of Pathology and Pathobiology
    The Fourth Military Medical University
    China
    wangra@fmmu.edu.cn
    GJCT

    Research Interest: Theory and Mechanisms of Carcinogenesis and Metastasis; Breast Cancer; Endocrinology


    More Info.
    Raj Kumar Koiri
    Assistant Professor
    Department of Zoology
    Dr. Hari Singh Gour Central University
    India
    rkkoiri@dhsgsu.ac.in
    GJCT

    Research Interest: To study the metabolic adaptation for survival occurring in the cancer cells

    More Info.
    Zbigniew Antosz
    Department of Pathology
    Regional Specialistic Hospital
    Poland
    antosz@mp.pl
    GJCT

    Research Interest: Histopathology, Anatomical pathology, Experimental oncology


    More Info.
    Zhu Shu
    Yale University
    USA
    shu.zhu@yale.edu
    GJCT

    Research Interest: To Study How Our Immune Systems Recognize “Self” (The Host) Or “Non-¬‐Self” (Foreign Material) Antigens, And How The Break Of These Processes Leads To The Consequent Disease Pathology, Including Infectious Diseases And Autoimmune Diseases.


    More Info.
    Ana Livia Silva Galbiatti
    Faculdade de Medicina de São José do Rio Preto
    Brazil
    analivia_sg@yahoo.com.br
    GJCT

    Research Interest: Head And Neck Cancer, Genetics, Molecular Biology, Cell Line, Chemoterapeutics, Genetic Polymorphisms


    More Info.
    Qinong Ye
    Professor
    Department of Medical Molecular Biology/Oncology
    Beijing Institute of Biotechnology
    China
    yeqn66@yahoo.com
    GJCT

    Research Interest: Molecular Basis Of Cancer; Cell Signaling; Epigenetics; DNA Damage Response


    More Info.
    Jose Maria Pereira de Godoy
    Assistant Professor
    Regional Medical School
    egional Medical School, São José do Rio Preto
    Brazil
    godoyjmp@riopreto.com.br
    GJCT
    Research Interest: Breast CancerRehabilitationLymphedema  
    More Info.
    Maryam Azimi Mohammadabadi
    Department of Immunology
    Tehran University of Medical Science
    Iran
    m-azimim@razi.tums.ac.ir
    GJCT

    Research Interest: Potential Therapeutic Applications of Arteether, a Semi-Synthetized Derivative of Artemisinin on a Murine Model of Breast Cancer. As a Result, I Have Got Some Experience Atan Area of Tumor Immunology/Immunotherapynamed "Chemoimmunotherapy". Chemoimmunotherapy is an Approach for the Treatment of Cancers in Whichthe Focus is to enhance the Efficacy of chemotherapeutic Agents by Concomitant Application of Compounds with Immunomodulatory Properties. Besides my Thesis Work, I Managed to Do a Course in Cellular Immunology with Professor Hassan, One of the Well-Knownimmunologists in Iran, so that i could also Work on Cellular Immunology Aspects of Tumors. Moreover, Considering the Reported Associations between Molecular Players such as CTLA-4, PDL-1 and also Different Micrornas in Tumor Progression, i am Currently Planning to further Study these Associations in order to improve the Efficacy of Tumor Immunotherapy

    More Info.
    View more
    mendeley

    Contribution of viruses to cancer and its global burden

    DOI Logo 10.17352/2581-5407.000025

    Published On: August 20, 2019 | Pages: 012 - 015

    Author(s): Shahzeb Khan Shaz*
    Abstract View Full Article View
    mendeley

    A Novel Nutrient Mixture Induces Apoptosis in Human Mesothelioma Cells (MSTO-211H) via Activation of Caspases

    DOI Logo 10.17352/2581-5407.000024

    Published On: April 09, 2019 | Pages: 007 - 011

    Author(s): M Waheed Roomi, Bilwa Bhanap, Aleksandra Niedzwiecki* and Matthias Rath
    Abstract View Full Article View
    mendeley

    Synthesis of Some Aryl Ketoxime Derivatives with their in vitro Anti-microbial and Cytotoxic Activity

    DOI Logo 10.17352/gjct.000023

    Published On: March 08, 2019 | Pages: 001 - 006

    Author(s): Oguzhan Karaosmanoglu, Burcu Butun*, Hakan Dal, Hulya Sivas and Kadriye Benkli
    Abstract View Full Article View
    mendeley

    Total Oncology is necessary for Japanese new era

    DOI Logo 10.17352/2581-5407.000022

    Published On: October 13, 2018 | Pages: 001 - 003

    Author(s): Tsuyoshi Shirakawa*
    Abstract View Full Article View
    mendeley

    Video Endoscopic Inguinal Lymphadenectomy: Refi ning surgical technique after ten years experience

    DOI Logo 10.17352/gjct.000021

    Published On: December 30, 2017 | Pages: 034 - 037

    Author(s): Marcos Tobias-Machado, Pericles Rios Auad*, Victor Corona, Igor Silva, Oseas de Castro Neves, Eliney Ferreira Faria, Pablo Matos, Alexandre Cesar Santos, Roberto Machado, Aurus Dourado and Hamilton de Campos Zampolli
    Abstract View Full Article View
    mendeley

    Role of tumor heterogeneity in drug resistance

    DOI Logo 10.17352/gjct.000020

    Published On: July 20, 2017 | Pages: 032 - 033

    Author(s): Dhruv Kumar*
    Abstract View Full Article View
    mendeley

    MEK Inhibitors in Combination with Immune Checkpoint Inhibition: Should we be Chasing Colorectal Cancer or the KRAS Mutant Cancer

    DOI Logo 10.17352/gjct.000019

    Published On: May 26, 2017 | Pages: 030 - 031

    Author(s): Julius Strauss*
    Abstract View Full Article View
    mendeley

    Angiosarcoma of the Scalp and Face: A Hard to Treat Tumor

    DOI Logo 10.17352/gjct.000018

    Published On: April 15, 2017 | Pages: 026 - 029

    Author(s): Jmour Omar*, Kochbati Lotfi , Ghith Sahar and Benna Farouk
    Abstract View Full Article View
    mendeley

    The Promise of Disease Management in Greece

    DOI Logo 10.17352/gjct.000017

    Published On: March 30, 2017 | Pages: 018 - 025

    Author(s): Konstantinos Stamatiou, Richard Lacroix, Eleni Almpani, Konstantinos Katsanos, Georgios Tzitzikos and Maria Saridi*
    Abstract View Full Article View
    mendeley

    Abrikossoff’s Tumour Mimicking a Neoplastic Tumour of the Breast: A Case Report

    DOI Logo 10.17352/gjct.000016

    Published On: March 20, 2017 | Pages: 015 - 017

    Author(s): Alassiri A*, Al Ali A, Vaysse C, Escourrou G, Vinet B and Rimailho J
    Abstract View Full Article View

     

    Clients' voices

    Readmore

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on GJCT